Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits

Cancer

Volumn 112, Issue 3, 2008, Pages 659-670

  Busse, Antonia ^a   Kraus, Marianne ^b   Na, Il Kang ^a   Rietz, Anika ^a   Scheibenbogen, Carmen ^a   Driessen, Christoph ^b   Blau, Igor Wolfgang ^a   Thiel, Eckhard ^a   Keilholz, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Apoptosis induction; B cell neoplasia; Interferon ; Proteasome inhibition; PS 341; Solid tumors

Indexed keywords

BORTEZOMIB; GAMMA INTERFERON; LACTACYSTIN; PROTEASOME; PROTEASOME BETA1; PROTEASOME BETA2; PROTEASOME BETA5; PROTEASOME INHIBITOR; PROTEIN SUBUNIT; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; CANCER CELL CULTURE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAJI CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR;

ACETYLCYSTEINE; APOPTOSIS; B-LYMPHOCYTES; BORONIC ACIDS; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTERFERON TYPE II; LYMPHOMA; MULTIENZYME COMPLEXES; MULTIPLE MYELOMA; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN SUBUNITS; PYRAZINES;

EID: 38749115417     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23224     Document Type: Article

References (20)

1. Adams J. Potential for proteasome inhibition in the treatment of cancer. Drug Discov Today. 2003;8:307-315.
2. Aki M, Shimbara N, Takashina M, et al. Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. J Biochem (Tokyo). 1994;115:257-269.
3. Belich MP, Glynne RJ, Senger G, Sheer D, Trowsdale J. Proteasome components with reciprocal expression to that of the MHC-encoded LMP proteins. Curr Biol. 1994;4:769-776.
4. Boes B, Hengel H, Ruppert T, Multhaup G, Koszinowski UH, Kloetzel PM. Interferon gamma stimulation modulates the proteolytic activity and cleavage site preference of 20S mouse proteasomes. J Exp Med. 1994;179:901-909.
5. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8:739-758.
6. Lee DH, Goldberg AL. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 1998;8:397-403.
7. Richardson PG, Hideshima T, Mitsiades C, Anderson K. Proteasome inhibition in hematologic malignancies. Ann Med. 2004;36:304-314.
8. Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005;4:290-296.
9. Masdehors P, Merle-Beral H, Magdelenat H, Delic J. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation. Leuk Lymphoma. 2000;38(5-6):499-504.
10. Geier E, Pfeifer G, Wilm M, et al. A giant protease with potential to substitute for some functions of the proteasome. Science. 1999;283:978-981.
11. Glas R, Bogyo M, McMaster JS, Gaczynska M, Ploegh HL. A proteolytic system that compensates for loss of proteasome function. Nature. 1998;392:618-622.
12. Verdoes M, Florea BI, Menendez-Benito V, et al. A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol. 2006;13:1217-1226.
13. Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34:374-378.
14. Frisan T, Levitsky V, Polack A, Masucci MG. Phenotype-dependent differences in proteasome subunit composition and cleavage specificity in B cell lines. J Immunol. 1998;160:3281-3289.
15. Benham AM, Neefjes JJ. Proteasome activity limits the assembly of MHC class I molecules after IFN-gamma stimulation. J Immunol. 1997;159:5896-5904.
16. Griffin TA, Nandi D, Cruz M, et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med. 1998;187:97-104.
17. Groettrup M, Standera S, Stohwasser R, Kloetzel PM. The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome. Proc Natl Acad Sci USA. 1997;94:8970-8975.
18. De M, Jayarapu K, Elenich L, Monaco JJ, Colbert RA, Griffin TA. Beta 2 subunit propeptides influence cooperative proteasome assembly. J Biol Chem. 2003;278:6153-6159.
19. Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA. 2002;99:14374-14379.
20. Varela N, Munoz-Pinedo C, Ruiz-Ruiz C, Robledo G, Pedroso M, Lopez-Rivas A. Interferon-gamma sensitizes human myeloid leukemia cells to death receptor-mediated apoptosis by a pleiotropic mechanism. J Biol Chem. 2001;276:17779-17787.